Allergies News and Research

Latest Allergies News and Research

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Angiotech Pharmaceuticals, Inc. and partner Athersys, Inc. announced positive results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction, more commonly referred to as a heart attack.

29 Jul 2010

IBM, UPMC partner to provide redesigned SmartRoom solution with service-oriented architecture

IBM and UPMC (University of Pittsburgh Medical Center) are teaming up to bring "smarter" hospital rooms to patients nationwide. Created by UPMC three years ago to bring the right patient information to the bedside when it's needed, the high-tech "smart room" now features new capabilities, namely a system for automatically organizing and prioritizing the work of nurses and other caregivers. Under a new agreement, IBM will be the exclusive sales channel for the SmartRoom solution and will help to implement the technology for customers.

29 Jul 2010

Mylan second-quarter adjusted diluted EPS increases to $0.37

Mylan Inc. today announced its financial results for the three and six months ended June 30, 2010.

29 Jul 2010

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Teva Respiratory today announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo. Furthermore, the safety profile of BDP HFA Nasal Aerosol was similar to placebo.

29 Jul 2010

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.

29 Jul 2010

POA releases consensus statement on CIRS-WDB

Policyholders of America released a consensus statement written by treating physicians and researchers in the field on the mechanism and treatment of illness found in people sickened by exposure to water-damaged buildings. This illness has been the subject of heated debate that has resulted in harsh allegations being lobbed at patients by experts hired by industry to cast doubt on the legitimacy of the illness.

28 Jul 2010

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

New York Times examines questions left unanswered by microbicide trial

The New York Times examines a set of questions raised by news out of the International AIDS Conference-AIDS 2010 last week that a microbicide gel containing the antiretroviral tenofovir used by women before and after sex helped reduce their risk of HIV infection by 39 percent.

28 Jul 2010

ITelagen to host, support and manage EHR for Allergy and Asthma Associates

ITelagen, a leading provider of electronic health record (EHR) hosting and management announced that it was selected by Allergy and Asthma Associates of Northern California, San Jose, CA to host, support and manage EHR for their medical practice. The solution includes hosting of patient data in ITelagen's SAS-70 Type II certified datacenter and unlimited IT support for staff members.

28 Jul 2010

InterMune second-quarter total revenue decreases to $5.9 million

InterMune, Inc. today announced results from operations for the second quarter and six months ended June 30, 2010. InterMune also highlighted its recent clinical development and business activities, and provided forward-looking financial guidance for 2010.

28 Jul 2010

QLT second-quarter total revenue increases 15.4% to $12.4 million

QLT Inc. today reported financial results for the second quarter ended June 30, 2010. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

27 Jul 2010

Global Fund director calls on emerging countries to invest more in programs to reduce HIV/AIDS, TB and malaria at AIDS 2010

On the final day of the International AIDS Conference-AIDS 2010 Friday, Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria called upon "China, India and other fast-growing economies" to chip in to help close the funding gap in efforts to battle HIV/AIDS, Agence France-Presse reports. "Until now, these countries have been recipients of AIDS funds, not donors," the news service writes.

27 Jul 2010

Albert Einstein College of Medicine receives research grant to help people with MDR-TB

For the third time in four months, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University a research grant aimed at helping people infected with multidrug-resistant tuberculosis. Taken together, all three NIH grants total $8.57 million.

27 Jul 2010

Alcon second-quarter global sales increase 12.5% to $1.89 billion

Alcon, Inc. reported that global sales rose 12.5 percent to $1.89 billion for the second quarter of 2010, or 11.3 percent excluding the impact of foreign exchange fluctuations and acquisitions. Revenue from acquisitions added 40 basis points to sales growth in the quarter, while foreign currency fluctuations added 80 basis points of growth.

27 Jul 2010

FDA approves Perrigo's OTC Cetirizine Cherry Syrup

Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC) Cetirizine Cherry Syrup, 1mg/ml. Shipments will begin in the Company's fiscal first quarter 2011. Cherry joins the currently available grape flavor cetirizine syrup in Perrigo's product portfolio, giving patients a choice of store brand flavors.

26 Jul 2010

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Vical Incorporated today announced that its prophylactic Vaxfectin®-formulated plasmid DNA (pDNA) vaccine against herpes simplex virus type 2 (HSV-2) protected mice against lethal challenge, provided sterilizing immunity and inhibited viral counts at both the primary and latent infection sites. The Vaxfectin® adjuvant substantially improved vaccine effectiveness. A related vaccine significantly reduced the recurrence of HSV-2 lesions in a therapeutic model using guinea pigs with latent infection.

26 Jul 2010

AANMA recommends a written asthma action plan before child self-medication

Students with asthma and allergies will pack more than just a lunchbox and bookbag when they start school this year: They'll be devising ways to keep their life-saving medications close at hand should they need them. No longer do they have to be locked up in the nurse's cabinet or the office. Laws passed in all 50 states now ensure students have the right to carry and use their asthma medications at school.

26 Jul 2010

Early HAART during TB treatment prolongs survival of untreated HIV-infected adults: CAMELIA study

A clinical trial in Cambodia has found it possible to prolong the survival of untreated HIV-infected adults with very weak immune systems and newly diagnosed tuberculosis (TB) by starting anti-HIV therapy two weeks after beginning TB treatment, rather than waiting eight weeks, as has been standard.

23 Jul 2010

National Jewish Health receives $31M NIH contract to study skin infections associated with atopic dermatitis

The National Institute of Allergy and Infections Disease has awarded a five-year $31 million contract to National Jewish Health, which is leading a consortium of academic medical centers seeking to better understand skin infections associated with atopic dermatitis. The researchers will focus on antibiotic-resistant staphylococcus aureus (MRSA) infections and widespread viral infections of the skin, both of which are more prevalent among atopic dermatitis patients.

23 Jul 2010

Study reveals link between allergies, asthma and old age

Mistaken for illnesses like bronchitis and emphysema, exacerbated by medications like aspirin, and overlooked by patients and doctors alike, asthma is a common and highly treatable condition in older adults. And while allergies tend to decrease with age, they also are frequently disregarded as a potential cause of misery for the elderly.

23 Jul 2010

Allergies News and Research

Latest Allergies News and Research

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

IBM, UPMC partner to provide redesigned SmartRoom solution with service-oriented architecture

Mylan second-quarter adjusted diluted EPS increases to $0.37

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

POA releases consensus statement on CIRS-WDB

Regeneron second-quarter total revenues increase to $115.9 million

New York Times examines questions left unanswered by microbicide trial

ITelagen to host, support and manage EHR for Allergy and Asthma Associates

InterMune second-quarter total revenue decreases to $5.9 million

QLT second-quarter total revenue increases 15.4% to $12.4 million

Global Fund director calls on emerging countries to invest more in programs to reduce HIV/AIDS, TB and malaria at AIDS 2010

Albert Einstein College of Medicine receives research grant to help people with MDR-TB

Alcon second-quarter global sales increase 12.5% to $1.89 billion

FDA approves Perrigo's OTC Cetirizine Cherry Syrup

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

AANMA recommends a written asthma action plan before child self-medication

Early HAART during TB treatment prolongs survival of untreated HIV-infected adults: CAMELIA study

National Jewish Health receives $31M NIH contract to study skin infections associated with atopic dermatitis

Study reveals link between allergies, asthma and old age

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Allergies News and Research

Latest Allergies News and Research

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Newsletters you may be interested in